Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Bladder Cancer

Journal Scan / Research · February 20, 2023

Efficacy of High- and Low-Dose Preoperative Ipilimumab Plus Nivolumab in Patients With Stage III Urothelial Cancer

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Nat. Med. 2023 Feb 02;[EPub Ahead of Print], J van Dorp, C Pipinikas, BBM Suelmann, N Mehra, N van Dijk, G Marsico, ML van Montfoort, S Hackinger, LM Braaf, T Amarante, C van Steenis, K McLay, A Daletzakis, D van den Broek, MW van de Kamp, K Hendricksen, JM de Feijter, TN Boellaard, RP Meijer, TG van der Heijden, N Rosenfeld, BWG van Rhijn, G Jones, MS van der Heijden

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading